Alpha 2.0
Login Register
» Authors » Eugene Schneider

Eugene Schneider

Explore the profile of Eugene Schneider including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 2417
Followers 0
Related Specialties
General Medicine
Neurology
Pharmacology
Top 10 Co-Authors
Nicholas J Viney
C Frank Bennett
Darryl C De Vivo
Jacqueline Montes
Claudia A Chiriboga
Richard S Finkel
Wildon Farwell
Kathie M Bishop
Brett P Monia
Shiangtung W Jung
Published In
N Engl J Med
Neurology
Nucleic Acid Ther
Neurol Ther
Genet Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen
McCaleb M, Hughes S, Grossman T, Frazer-Abel A, Jung B, Yin L, et al.
Immunobiology . 2025 Feb; 230(2):152876. PMID: 39893955
An over-active alternative complement pathway has been implicated in the pathophysiology of multiple diseases, including IgA nephropathy and geographic atrophy secondary to age related macular degeneration. In first-in-human double-blind, placebo-controlled...
2.
A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema
Petersen R, Bordone L, Riedl M, Tachdjian R, Craig T, Lumry W, et al.
Allergy . 2023 Nov; 79(3):724-734. PMID: 38009241
Background: Hereditary angioedema (HAE) is a potentially fatal disease characterized by unpredictable, recurrent, often disabling swelling attacks. In a randomized phase 2 study, donidalorsen reduced HAE attack frequency and improved...
3.
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Coelho T, Marques Jr W, Dasgupta N, Chao C, Parman Y, Franca Jr M, et al.
JAMA . 2023 Sep; 330(15):1448-1458. PMID: 37768671
Importance: Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective: To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, And Participants:...
4.
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen
Coelho T, Cruz M, Chao C, Parman Y, Wixner J, Weiler M, et al.
Neurol Ther . 2022 Dec; 12(1):267-287. PMID: 36525140
Introduction: Hereditary transthyretin (ATTRv) amyloidosis is a rare, severe, progressive, debilitating, and ultimately fatal disease caused by systemic deposition of transthyretin (TTR) amyloid fibrils. ATTRv amyloidosis occurs in both males...
5.
Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis
Diep J, Yu R, Viney N, Schneider E, Guo S, Henry S, et al.
Br J Clin Pharmacol . 2022 Jul; 88(12):5389-5398. PMID: 35869634
Aims: Transthyretin-mediated amyloidosis is a progressive and fatal disease caused by the build-up of misfolded transthyretin (TTR) protein. Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotide targeting TTR messenger...
6.
Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides
Wang Y, Diep J, Yu R, Hurh E, Karwatowska-Prokopczuk E, Schneider E, et al.
J Clin Pharmacol . 2022 Jul; 63(1):21-28. PMID: 35801818
The pharmacokinetics (PK) of 2'-O-methoxyethyl and phosphorothioate antisense oligonucleotides (ASOs), with or without N-acetyl galactosamine conjugation, have been well characterized following subcutaneous or intravenous drug administration. However, the effect of...
7.
Inhibition of Prekallikrein for Hereditary Angioedema
Fijen L, Riedl M, Bordone L, Bernstein J, Raasch J, Tachdjian R, et al.
N Engl J Med . 2022 Mar; 386(11):1026-1033. PMID: 35294812
Background: Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal. Selective inhibition of plasma prekallikrein production by antisense oligonucleotide treatment (donidalorsen) may reduce the...
8.
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study
Finkel R, Chiriboga C, Vajsar J, Day J, Montes J, De Vivo D, et al.
Lancet Child Adolesc Health . 2021 Jun; 5(7):491-500. PMID: 34089650
Background: Nusinersen showed a favourable benefit-risk profile in participants with infantile-onset spinal muscular atrophy at the interim analysis of a phase 2 clinical study. We present the study's final analysis,...
9.
Improving and Understanding the Hydrogen Evolving Activity of a Cobalt Dithiolene Metal-Organic Framework
Chen K, Downes C, Schneider E, Goodpaster J, Marinescu S
ACS Appl Mater Interfaces . 2021 Mar; 13(14):16384-16395. PMID: 33788537
Despite the promising previous reports on the development of electrocatalytic dithiolene-based metal-organic frameworks (MOFs) for the hydrogen evolution reaction (HER), these materials often display poor reproducibility of the HER performance...
10.
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Coelho T, Ando Y, Benson M, Berk J, Waddington-Cruz M, Dyck P, et al.
Neurol Ther . 2021 Feb; 10(1):375-389. PMID: 33638113
Introduction: AKCEA-TTR-L is a ligand-conjugated antisense (LICA) drug in development for the treatment of hereditary transthyretin amyloidosis (hATTR), a fatal disease caused by mutations in the transthyretin (TTR) gene. AKCEA-TTR-L...